A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 03 Jun 2024
At a glance
- Drugs BL M05D1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 26 May 2024 Status changed from not yet recruiting to recruiting.
- 09 Apr 2024 New trial record